Combating *Acanthamoeba* spp. cysts: what are the options?

Ayaz Anwar, Naveed Ahmed Khan* and Ruqaiyyah Siddiqui

Abstract

*Acanthamoeba* spp. are protist pathogens and causative agents of serious infections including keratitis and granulomatous amoebic encephalitis. Its ability to convert into dormant and highly resistant cysts form limits effectiveness of available therapeutic agents and presents a pivotal challenge for drug development. During the cyst stage, *Acanthamoeba* is protected by the presence of hardy cyst walls, comprised primarily of carbohydrates and cyst-specific proteins, hence synthesis inhibition and/or degradation of cyst walls is of major interest. This review focuses on targeting of *Acanthamoeba* cysts by identifying viable therapeutic targets.

Keywords: *Acanthamoeba*, Cyst, Encystation, Excystation, Therapeutic targets

Background

*Acanthamoeba* spp. are opportunistic free living amoebae, commonly found in water and soil. *Acanthamoeba* exist in two forms: (i) an active trophozoite stage and (ii) a resistant double-walled cyst stage (Fig. 1). Encystment usually occurs on exposure of *Acanthamoeba* to harsh conditions such as change in pH, lack of nutrients, treatment with therapeutic agents etc. [1]. *Acanthamoeba* produce two major infections, namely *Acanthamoeba* keratitis (AK), a painful sight-threatening infection, and granulomatous amoebic encephalitis (GAE), a rare but fatal infection of the central nervous system resulting in death in more than 95% of cases [2]. AK is generally associated with contact lens wearers and remains an elusive problem in spite of advances in antimicrobial chemotherapy and eye care [3]. AK is still considered as a rare disease and is usually diagnosed late which makes it harder to treat [4]. The current course of managing *Acanthamoeba* keratitis infections includes a combination of antimicrobial agents such as biguanides and diamidines, while in some cases a topical azole and/or neomycin is added in combination [5]. The use of corticosteroids is controversial as they can cause decline in immunological response of the patients, but some reports show their use can lead to improvement in therapy [6–8]. Based upon the severity of AK and as a last resort, the only viable surgical option is penetrating keratoplasty. Despite advances in combination therapies and surgery, cyst resistance to therapeutic agents and recurrence of infection due to encystment remains a challenge that is yet to be addressed. A major obstacle in overcoming treatment of *Acanthamoeba* infections is the sturdy nature of the cysts and their resistance to physical and chemical damage. Herein, we describe strategies that can be utilised to target *Acanthamoeba* cysts.

Targeting the cyst wall

*Acanthamoeba* cysts are double-walled, consisting of an ectocyst and an endocyst. The ectocyst is formed during the initial stage of encystment and appears as an amorphous, discontinuous layer while the endocyst has a fine granular texture, and is uniformly thicker as compared to the former [9]. As the cyst walls provide a physical barrier for drugs to target amoeba residing within the shell, it is important to understand their biochemistry. Once we understand the basic molecular structure of the hardy shell, it is possible to design strategies to degrade cyst walls and kill the parasite residing within the shell. Using radiolabelling, several studies have been conducted to understand the chemical composition of *Acanthamoeba* cysts, and it is reported that the endocyst consists of polysaccharides, mainly cellulose, while the ectocyst consists of a mixture of proteins and polysaccharides [10, 11]. *Acanthamoeba* cyst walls contain 33% proteins, 4–6% lipids, 35% carbohydrates.

---

* Correspondence: naveed5438@gmail.com
Department of Biological Sciences, School of Science and Technology, Sunway University, Subang Jaya, Malaysia

© The Author(s), 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
(mostly cellulose), 8% ash, and 20% unidentified material [10]. Among carbohydrates, cellulose was identified as a major constituent. The precursor of cellulose is glucose that is incorporated into the cell wall as β(1 → 4)-glucans (i.e. cellulose) (Fig. 2) [11]. In contrast, our studies regarding gas chromatography tandem mass spectrometry (GC-MS) based carbohydrate analysis of Acanthamoeba castellanii belonging to the T4 genotype identified galactose as a major constituent of the cyst wall, instead of glucose [12]. The carbohydrate components of the cyst wall showed that it contained about 48% galactose and 44% glucose. Furthermore, linkage analysis revealed the presence of 3-linked galactopyranose (1,3-linked galactose) as the highest constituent of the cyst wall (about 29%), while 4-linked glucopyranose (β-1,4-linked glucose, i.e. likely cellulose) was 22% as the second major component [12]. These findings provide novel targets (3-linked galactopyranose) against Acanthamoeba cyst walls, in addition to the perceived cellulose (1,4-linked glucose) as the only target to degrade Acanthamoeba cysts. The use of enzymatic catalysts that can hydrolyse complex sugars can serve as potential agents to target cyst walls via degradation of specific sugar linkages. Once cyst walls are degraded, it is easier to target Acanthamoeba. This concept was proven by our team [13] who showed that targeting Acanthamoeba cysts with cellulase enzyme in combination with chlorhexidine can effectively abolish Acanthamoeba cyst viability. In contrast, cellulase or chlorhexidine alone had limited effects against Acanthamoeba cysts [13]. As the presence of cellulose is limited to plants, fungi, and some bacteria/protists, cellulose-specific drugs should exhibit limited, if any, side effects on host cells. In another report, Lorenzo-Morales et al. [14] established

---

**Fig. 1** Life cycle of Acanthamoeba. Under harsh conditions, Acanthamoeba trophozoites transform into a resistant cyst form, while favourable conditions permit vegetative growth. a Transmission electron micrograph of trophozoite stage of Acanthamoeba. b Transmission electron micrograph of Acanthamoeba cyst. Abbreviations: Nu, nucleus; V, vacuoles; M, mitochondria; PM, plasma membrane; OM, outer membrane; IM, inner membrane

---

**Fig. 2** Cyst wall biosynthesis involves polysaccharides and cyst-specific protein synthesis

---

**Fig. 2** Cyst wall biosynthesis involves polysaccharides and cyst-specific protein synthesis
the role of glycogen phosphorylase in encystment as a contributor to glycogen breakdown, and demonstrated its requirement for formation of the endocyst [14]. Hence, utilizing hydrolytic enzymes such as specific glycosidases to do nature’s work in favour of particular application against resistant pathogens holds promise in the development of novel and target-specific therapeutic agents. The advantage of using specific enzymes for targeting particular sugar linkages is of key interest. Based upon chemical composition of the target, one enzyme can be found to be more useful against a given species than the other. For example, endo β-galactofuranosidase obtained from Bacillus spp. is specifically shown to degrade β-1-6 galactofuranoside linkages in the polysaccharide of Fusarium spp. [15]. Similarly, as Acanthamoeba cyst walls contains about 48% galactose [12], targeting 1,3-linked galactose linkage with a specific enzyme may turn out to be a breakthrough in degrading Acanthamoeba cysts. Such enzymes of glycoside hydrolase class may serve as potential agents to target cyst walls due to their specificity towards degrading gal-glu and gal-gal linkages. Furthermore, the non-toxicity of these enzymes to mammalian cells makes them an ideal candidate for evaluation of cyst-degrading agents. Among carbohydrate-targeting drugs, research in diabetes has received the most attention. A plethora of drugs are available and/or have been tested for antidiabetic effects that function by metabolizing sugars and/or inhibit their synthesis. As some of the compounds may exhibit broad-spectrum activity, it is reasonable to determine their effects against carbohydrate-linked polymer and/or its synthesis in the cyst walls of Acanthamoeba. In particular, as cyst walls of Acanthamoeba contain glucose as another major constituent, the glyco-targeting antidiabetic drugs may be of value in testing against cyst walls synthesis. Although antidiabetic drugs are consisting of a variety of functional agents such as glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, sulfonyl ureas, insulin, incretin mimetic etc. to name a few, the depletion of cyst walls by deconstruction of sugar linkages or inhibiting polymer synthesis is worth investigating. Sulfonly ureas such as glimepiride, biguanides such as metformin, glucosidase inhibitors such as acarbose, meglitinides such as glipunonization agents, DPP4 inhibitors such as vildagliptin, insulin secreting compounds and its biomimetics such as cinnamic acid and its derivatives, should be tested against Acanthamoeba cysts. Furthermore, the other major composite of cyst walls consists of acid-resistant proteins [10]. It is a cyst-specific protein of 21 kDa (CSP21) molecular weight, which is expressed in the process of encystment and absent in the trophozoite form of A. castellanii and its biosynthesis is regulated at the mRNA level [16]. The development in genetic engineering also provides a useful tool to study mechanistic target against Acanthamoeba cyst protein [16, 17]. For example, the development of anti-CSP21 antibodies is achieved to characterize Acanthamoeba taxonomy via specific binding to CSP21 [16, 17]. Behera et al. [18] carried out a more detailed protein analysis for both trophozoite and cyst forms of Acanthamoeba which suggests newer entities for targeting protein pathways. Based on MALDI-TOF/TOF analysis, two proteins from trophozoites were identified as hypothetical protein ACA1 and eukaryotic porin protein, while another pair of proteins were identified from cysts as chaperone protein DnaK and chaperonin protein, respectively. The exact functions of these proteins are not fully understood so far, but their anticipated roles are suggested to be as follows: eukaryotic porin proteins may have important role in the efflux of toxic metabolites and exudates during encystment and may also have an effect on pathogenicity. Similarly, proteins such as chaperone protein DnaK and chaperonin protein which belongs to heat shock proteins class, may have a role in folding of cyst specific proteins in cysts [18]. Hence, altering these genes’ expression may provide a means to control the life cycle of Acanthamoeba.

**Nanoparticles and antiacanthamoebic drugs**

The recent decline in development of newer antimicrobial agents has contributed to increased disease burden as well as mortality rate and drug resistance [19]. As Acanthamoeba infections are considered rare, the development of antiacanthamoebic agents faces an even worse scenario when compared to other communicable diseases. The discovery of various antiacanthamoebic compounds tested in vitro has not been able to enter mainstream drug development due to their limited in vivo potential as well as general inefficacy against the cyst stage. A comprehensive review by our team [20] identifies and presents targets and mechanism of action of numerous drugs against Acanthamoeba although their in vivo efficacy remains undetermined. A few cases of re-purposing drugs are also reported to work well against Acanthamoeba, including some antibacterial agents: polymyxin B [21, 22], cefazolin [23], meropenem [24], moxifloxacin [25]; antifungal compounds: amphotericin B [26], azoles [27, 28]; and antineoplastic agents: alkylphosphocholines [29, 30]. Our studies also highlighted the use of re-purposed drugs against Acanthamoeba [31]. These included amiodarone, amiodipine, apomorphine, digoxin, haloperidol, loperamide, prochlorperazine, and procyclidine. Re-purposing of drugs has the advantage of an early start for new applications as they have been approved clinically for other diseases. Finding new sources of antiacanthamoebic drugs has also led several groups including ours to research natural
products, and various plant extracts have been tested to exhibit cytotoxicity against *Acanthamoeba* [32–35].

Nanotechnology is currently serving as a pivotal tool in different scientific ventures. Its applications in chemistry and biology have exceptionally emerged as potential source of novel solutions. The drastic contrast in chemical and biological properties of nanomaterials, as compared to their bulk counterparts, have pave their path in biomedicines for applications such as diagnosis, therapy, drug delivery etc. Nanomaterials can be simply described as materials and devices which lie within the range of nanometer scale [36]. The most utilized examples of nanomaterials are carbon nanotubes, nanoparticles, nanorods, liposomes etc. Nanomaterials have also recently been successfully employed extensively against numerous infectious diseases [37]. These are promising drug delivery systems due to their small size and cell penetration, and are associated with enhancing drug bioavailability and hence increasing their antimicrobial potency, reducing drug resistance by specifically targeting any cellular function, and increasing their stability in general (Fig. 3) [38]. The uses of nanomaterials against *Acanthamoeba* are so far limited to only a few examples. In our study liposomal complexation of pentamidine isethionate and ergosterol is shown to enhance its anti- *Acanthamoeba* activity [39]. In another report, silver nanoparticles have been successfully used to inhibit microbial growth and colonization on contact lenses, which shows the potential of nanoparticles in the development of contact lens solutions [40]. A formulation of nanoe-mulsion from plant extract of *Pterocaulon balansae* is used as a treatment of ocular AK. The extract is shown to contain high ratio of coumarin compounds which are naturally occurring plant products [35]. This report suggests that coumarin, polyphenols, and other natural products conjugated with nanomaterials hold promise against *Acanthamoeba* and possibly their cyst. The conjugation of chlorhexidine with gold nanoparticles has demonstrated a significant increase in its amoebicidal and cysticidal potency, with minimal associated host cell cytotoxicity by our group [41]. Metal oxide nanoparticles such as TiO$_2$, Fe$_2$O$_3$, ZnO etc. are frequently used as antimicrobial agents due to their capability to generate reactive oxygen species (ROS) in the presence of UV light, which makes them an ideal candidate for application against microbes via photochemotherapy [42]. Based on these reports, nanomaterials, especially nanoparticles conjugated with natural products and broad spectrum antibacterial drugs, can be evaluated as a new generation of antimicrobial agents against *Acanthamoeba* infections. Furthermore, if constructed with cyst-targeting agents such as those discussed here, along with drug conjugation, they may produce effective nanomedicine formulations against *Acanthamoeba*. For example, if antimicrobial agents are coated on the surface of nanoparticles and those particles are fabricated with reagents having affinity with mannose-binding proteins, cellulose, galactose-polymer, polyhexamethylene biguanide (PHMB), neomycin, and other aforementioned compounds, this may result in enhanced overall anti- *Acanthamoeba* activity.

**Targeted anti- *Acanthamoeba* therapies**

Targeting vehicles such as antibodies for a specific antigen, peptides enabling cells penetration and crossing barriers such as the blood-brain barrier (BBB), parasite specific biosynthetic pathways enzymes inhibitors, and mannose-conjugated antimicrobial agents, are important strategies for the targeted delivery of chemotherapeutic agents against *Acanthamoeba* infections. These avenues should provide tremendous advantages over non-specific
therapies due to minimal side effects and host cells cytotoxicity. The targeted chemotherapy against *Acanthamoeba* has received limited attention, and only a few reports are published making it an open field for further research. For example, monoclonal IgA antibodies were shown to protect against AK, while the mode of protection was the inhibition of adhesion of *Acanthamoeba* to the corneal epithelium [43]. Drugs conjugated with parasite-specific adhesins can be of value in specific delivery of compounds. For example, mannose-binding protein on the surface of *Acanthamoeba* is an efficient target for delivery of mannose-conjugated drugs. A porphyrin molecule conjugated with mannose was used successfully in our study for the development of photodynamic therapy (PDT) against *Acanthamoeba* [44]. PDT is another promising technology which can be used to target resistant pathogens. The mode of PDT action is based on activation of photosensitizing compound with light of an appropriate wavelength to generate singlet oxygen and/or reactive oxygen species (ROS) which are known to induce cell death in the target pathogen. Targeted PDT is expected show high specificity towards the target cells and minimally toxic effects due to not binding to host cells. However, such discrimination is sometimes difficult to achieve, hence the selective targeting of pathogenic *Acanthamoeba* remains a major concern. Additionally, more effective photosensitizers which can generate a burst of toxins at shorter pulsed interval of light will add practicality in their clinical applications. Hence, further work is needed to conjugate *Acanthamoeba* antibodies with more effective photoactivated compounds and/or drugs in the development of better antiacanthamoebic strategies. Another challenge in the successful treatment of amoebal brain infection is the inefficacy of drugs to cross the BBB to reach the site of infection and target the parasite. Cheng et al. [45] developed transactivator of transcription (TAT) peptide-modified gold nanoparticles, which are demonstrated to be capable of crossing the BBB and efficiently delivering drugs to brain tumour tissues [45]. These suggested strategies have a strong rationale, and if utilized smartly, could yield a breakthrough in treatment of infections due to *Acanthamoeba* as well as against other CNS pathogens. However, along with drug development, drugs administration also plays a significant role in the effectiveness of their performance, hence there is a desperate need to revisit the overall drug designing protocol against *Acanthamoeba* infections for efficient and more practical options.

**Conclusions**

In summary, *Acanthamoeba* infections are complex biological disorders associated with very high rate of morbidity and mortality which require therapeutic strategies that recognize and respond to their dynamic nature. The molecular target-inspired approaches such as those presented above, in our opinion represent appealing frontiers for research and need to be evaluated further to develop more effective therapeutic options against *Acanthamoeba* as a whole and in particular against its cyst stage.

**Acknowledgements**

We are grateful to Professor Ed Jarroll, City University New York, USA, and Dr Sutherland Maciver, University of Edinburgh, UK for helpful discussions and constructive comments.

**Funding**

Not applicable.

**Availability of data and materials**

Not applicable.

**Authors’ contributions**

RS proposed the concept. AA searched the literature and prepared the first draft of the manuscript under the supervision of NK. RS and NK corrected the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 19 September 2017 Accepted: 5 December 2017

Published online: 09 January 2018

**References**

1. Khan NA. *Acanthamoeba*: biology and increasing importance in human health. FEMS Microbiol Rev. 2006;30:564–95.
2. Martínez AI, Visvesvara GS. Free-living, amphizoic and opportunistic amebas. Brain Pathol. 1997;7(1):583–98.
3. Chawla A, Armstrong M, Carely F. *Acanthamoeba* keratitis - an increasing incidence. Cont Lens Anterior Eye. 2014;37(2):120.
4. Lorenzo-Morales J, Khan NA, Walchlik J. An update on *Acanthamoeba* keratitis: diagnosis, pathogenesis and treatment. Parasite. 2015;22:10.
5. Oldenburg CE, Acharya NR, Tu EY, Zegans ME, Mannis MJ, Gaynor BD, et al. Practice patterns and opinions in the treatment of *Acanthamoeba* keratitis. Cornea. 2011;30(12):1363.
6. Park DH, Palay DA, Daya SM, Stulting RD, Krakher JH, Holland EJ. The role of topical corticosteroids in the management of *Acanthamoeba* keratitis. Cornea. 1997;16(3):277–83.
7. McClellan K, Howard K, Niederkorn JY, Alizadeh H. Effect of steroids on *Acanthamoeba* cysts and trophozoites. Invest Ophthalmol Vis Sci. 2001;42(12):2885–93.
8. Rahimi F, Hashemian SM, Tafi MF, Mehtjerdi MZ, Safizadeh MS, Pour EK, et al. Chlorhexidine monotherapy with adjunctive topical corticosteroids for *Acanthamoeba* keratitis. J Ophthalmic Vis Res. 2015;10(2):106.
9. Bowers B, Korn ED. The fine structure of *Acanthamoeba* castellani (Neff strain). J Cell Biol. 1969;41(3):786–805.
10. Neff RJ, Neff RH. The Biochemistry of amoebic encystment. Symp Soc Exp Biol. 1969;23:51–81. PMID: 4243920
11. Weisman RA. Differentiation in *Acanthamoeba* castellani. Annu Rev Microbiol. 1976;30:189–219.
12. Dudley R, Jarroll EL, Khan NA. Carbohydrate analysis of *Acanthamoeba* castellani. Exp Parasitol. 2009;122:338–43.
13. Abjani F, Khan NA, Yousuf FA, Siddiqui R. Targeting cyst wall is an effective strategy in improving the efficacy of contact lens disinfecting.
solutions against *Acanthamoeba castellanii* cysts. Cont Lens Anterior Eye. 2016;39(3):239–43.

14. Lorenzo-Morales J, Klicsickova J, Martinez-Carreto E, De Pablos LM, Profotova B, Nohnykova E, et al. Glycogen phosphorylase in *Acanthamoeba* spp.: determining the role of the enzyme during the encystment process using RNA interference. Eukaryot Cell. 2008;7(3):509–17.

15. Iwahara S, Mishima T, Ramli N, Takegawa K. Degradation of β1–6 galactofuranoside linkages in the polysaccharide of *Fusarium* sp. M7-1 by endo-β-galactofuranosidase from *Bacillus* sp. Biosci Biotechnol Biochem. 1996;60(6):957–61.

16. Hirukawa Y, Nakanoh H, Izumi S, Tsunohu T, Tomino S. Structure and properties of natural and marketed honey in Pakistan. Asian Pac J Trop Biomed. 2013;57(8):3561–8.

17. Chen L, Orfeo T, Gilmartin G, Bateman E. Mechanism of cyst specific protein of *Acanthamoeba castellanii*. Biochim Biophys Acta. 1998;1381(1):47–56.

18. Behera HS, Satpathy G. Characterisation and expression analysis of trophozoite and cyst proteins of *Acanthamoeba* spp. isolated from *Acanthamoeba keratitis* (AK) patient. Mol Biochem Parasitol. 2016;205(1):29–34.

19. World Health Organization. Mortality report. 2002. http://www.who.int/whr/2002/en/whr2002_annex2pdf.pdf?ua=1. Accessed on 20 June 2017.

20. Siddiqui R, Aqeel Y, Khan NA. The development of drugs against *Acanthamoeba* infections. Antimicrob Agents Chemother. 2016;60(1):6411–40.

21. Casemore DP. Sensitivity of *Harmanella* (*Acanthamoeba*) to 5-fluorocytosine, hydroxytethanolamine, and other substances. J Clin Pathol. 1970;23(8):649–52.

22. Nagington J, Richards J. Chemotherapeutic compounds and *Acanthamoeba* from eye infections. J Clin Pathol. 1976;29(7):648–51.

23. Sharma R, Jhanji V, Satpathy G, Sharma N, Khokhar S, Agarwal T. Coinfection with *Acanthamoeba* and Pseudomonas in contact lens-associated keratitis. Optom Vis Sci. 2013;90(2):e3–5.

24. Lackner P, Beer R, Brosenauer G, Helbok R, Pflauser B, Brennecis C, et al. Acute granulomatous *Acanthamoeba* encephalitis in an immunocompetent patient. Neurocrit Care. 2010;12(1):91–4.

25. Sheng WH, Hung CC, Huang HH, Liang SY, Cheng YJ, Ji DD, et al. First case of granulomatous aemetic encephalitis caused by *Acanthamoeba castellanii* in Taiwan. Am J Trop Med Hyg. 2009;81(1):277–9.

26. Wala R, Montoya JG, Visvesvera GS, Booton GC, Doyle RL. A case of successful treatment of cutaneous *Acanthamoeba* infection in a lung transplant recipient. Transpl Infect Dis. 2007;9(1):51–4.

27. Ishibashi Y, Matsumoto Y, Kabata T, Watanabe R, Hommura S, Yasuraoka K, et al. Oral itraconazole and topical miconazole with debridement for *Acanthamoeba* keratitis. Am J Ophthalmol. 1990;109(2):121–7.

28. Gupta S, Shrivastava RM, Tandon R, Gogia V, Agarwal P, Satpathy G. Role of voriconazole in combined *Acanthamoeba* and fungal corneal ulcer. Cont Lens Anterior Eye. 2011;34(5):287–9.

29. Walochnik J, Duchêne M, Seifert K, Obwaller A, Hottokowitz T, Wiedermann G, et al. Cytotoxic activities of alkylphosphocholines against clinical isolates of *Acanthamoeba* spp. Antimicrob Agents Chemother. 2002;46(3):695–701.

30. Seal D. Treatment of *Acanthamoeba* keratitis. Expert Rev Antiviral Ther. 2003;1(2):205–8.

31. Baig AM, Iqbal J, Khan NA. In vitro efficacies of clinically available drugs against growth and viability of an *Acanthamoeba castellanii* isolate belonging to the T4 genotyp. Antimicrob Agents Chemother. 2013;57(8):3561–7.

32. Roongruangchai J, Sookkua T, Kummalue T, Roongruangchai K. *Pouzolzia indica* methanic extract fraction and Povidone-iodine induced changes in the cyst of *Acanthamoeba* spp.: light and electron microscopic studies. J Med Assoc Thai. 2011;94(11):1492.

33. Siddiqui R, Warsame AA, Khan NA. Antibacterial and anti-*Acanthamoeba* properties of *Catha edulis* (Khat). J Bacterial Parasitol. 2012;3(1).

34. Youssuf FA, Mehmod MH, Malik A, Siddiqui R, Khan NA. Anticanthamoebaic properties of natural and marketed honey in Pakistan. Asian Pac J Trop Biomed. 2016;6(1):967–72.

35. Paratierr LF, Brazil NT, Faber K, Medeiros-Neves B, von Poser GL, Rott MB, et al. Nanoemulsions containing a coumarin-rich extract from *Pterocaulon balansae* (Asteraceae) for the treatment of ocular *Acanthamoeba* keratitis. AAPS PharmSciTech. 2017;18(3):721–8.

36. Buzet C, Pachecho I, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007;2:17–71.

37. Zazo H, Colino CJ, Lanao JM. Current applications of nanoparticles in infectious diseases. J Control Release. 2016;248:102–3.

38. Mainent P, Le Verge R, Sado P, Couvreur P, Devissaguet JP. Disposition kinetics and oral bioavailability of vincamine-loaded polyacrylate nanoparticles. J Pharm Sci. 1986;75:955–8.

39. Siddiqui R, Syed A, Tomas S, Prieto-Garcia J, Khan NA. Effect of free versus liposomal-complexed pentamidine 6isethionate on biological characteristics of *Acanthamoeba castellanii* in vitro. J Med Microbiol. 2009;58(3):327–30.

40. Wilcox MD, Hume EB, Vijay AK, Petcovich R. Ability of silver-impregnated contact lenses to control microbial growth and colonisation. J Optom. 2010;3(1):143–8.

41. Aqeel Y, Siddiqui R, Anwar A, Shah MR, Khan NA. Gold nanoparticle conjugation enhances the anticanthamoebaic effects of chlorhexidine. Antimicrob Agents Chemother. 2016;60(3):1283–8.

42. Imran M, Muzzamm AG, Habib A, Matin A. Synthesis, characterization and amebicidal potential of locally synthesized TiO2 nanoparticles against pathogenic *Acanthamoeba* trophozoites in vitro. J Photochem Photobiol B Biol. 2016;159:125–32.

43. Leher H, Zaragoza F, Taherzadeh S, Alizadeh H, Niederkorn JY. Monoclonal IgA antibodies protect against *Acanthamoeba* keratitis. Exp Eye Res. 1999;69(1):75–84.

44. Aqeel Y, Siddiqui R, Anwar A, Shah MR, Khoja S, Khan NA. Photochemotherapeutic strategy against *Acanthamoeba* infections. Antimicrob Agents Chemother. 2015;59(6):3031–41.

45. Cheng Y, Dai Q, Mosheed RA, Fan X, Wegscheid ML, Wainwright DA, et al. Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small. 2014;10(24):5137–50.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit